

App. No. 09/345,815
Amdt. dated Sept. 18, 2003
Reply to Office action of June 16, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 4 (previously presented): The method of claim 15 wherein the contacting is performed *in vitro*.

Claim 5 (previously presented): The method of claim 15 wherein the contacting is performed *in vivo*.

Claim 10 (currently amended): The method of claim 15 wherein the compound is 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline or 4-(3'-bromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.

Claim 11 (previously presented): The method of claim 15 wherein the cells are mammalian.

Claim 12 (previously presented): The method of claim 15 wherein the cells are human.


Claim 13 (previously presented): The method of claim 15 wherein the cells are avian.

Claim 15 (currently amended): A method for specifically inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with an effective inhibitory amount of a compound of formula I:

App. No. 09/345,815

Amdt. dated Sept. 18, 2003

Reply to Office action of June 16, 2003



wherein

X is HN, R₁₁N, S, O, CH₂, or R₁₁CH;R₁₁ is hydrogen (C₁-C₄)alkyl, or (C₁-C₄)alkanoyl;

R₁-R₈ are each independently hydrogen, hydroxy, mercapto, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, (C₁-C₄)alkylthio, or halo; wherein two adjacent groups of R₁-R₅ together with the phenyl ring to which they are attached may optionally form a fused ring, ~~for example forming a naphthyl or a tetrahydronaphthyl ring~~; and further wherein the ring formed by the two adjacent groups of R₁-R₅ may optionally be substituted by 1, 2, 3, or 4 hydroxy, mercapto, amino, nitro, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, (C₁-C₄)alkylthio, or halo; and

R₉ and R₁₀ are each independently hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo, or (C₁-C₄)alkanoyl; or R₉ and R₁₀ together are methylenedioxy; or a pharmaceutically acceptable salt thereof.

Claim 16 (new): The method of claim 15 wherein the compound is

4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline or
a pharmaceutically acceptable salt thereof.